VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ISPC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ISPCiSpecimen Inc.
$2.67$370762
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksISPCBalance Sheet

iSpecimen Inc. (ISPC) Balance Sheet

8Y historyFree accessUpdated daily

The company's financial position has deteriorated significantly, with total assets falling from $15.8M in 2023Q4 to $6.6M in 2026Q1, while accumulated losses have pushed retained earnings to -$84.6M.

ISPC Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Total Current Assets3.48M6.95M3.59M8.24M19.68M32.95M3.47M1.58M2.3M
Cash & Short-Term Investments2.82M6.88M1.88M5.01M15.31M27.74M695.91K53.89K1.13M
Cash Only2.82M6.88M1.88M2.34M15.31M27.74M695.91K53.89K1.13M
Short-Term Investments0002.66M00000
Accounts Receivable132.85K48.3K1.44M2.94M3.93M4.88M2.36M1.39M1.03M
Days Sales Outstanding59.919.1456.75108.12137.75160.04105.19118.2685.2
Inventory000000054.91K47.29K
Days Inventory Outstanding-------9.427.31
Other Current Assets532.19K25.46K264.89K292.08K140.87K0079.23K0
Total Non-Current Assets3.13M2.58M5.76M7.58M4.94M2.77M2.74M2.63M1.74M
Property, Plant & Equipment277.05K294.7K421.54K321.64K410.54K32.78K75.59K119.92K149.1K
Fixed Asset Turnover3.27x6.55x22.04x30.87x25.34x339.69x108.27x35.84x29.48x
Goodwill000000000
Intangible Assets2.84M1M5.33M7.23M4.5M2.71M2.63M2.31M1.44M
Long-Term Investments0000000179.52K127K
Other Non-Current Assets12.1K1.28M12.1K27.6K27.6K27.6K27.6K207.12K154.6K
Total Assets6.61M9.53M9.35M15.82M24.62M35.72M6.21M4.21M4.04M
Asset Turnover0.13x0.20x0.99x0.63x0.42x0.31x1.32x1.02x1.09x
Asset Growth %-70.9%1.94%-40.89%-35.74%-31.08%475.22%47.34%4.2%-
Total Current Liabilities5.6M6.23M5.77M6.05M4.28M2.51M22.14M15.76M11.3M
Accounts Payable4.71M5.36M4.2M3.93M2.46M832.68K1.79M737.79K696.91K
Days Payables Outstanding1.31K1.03K288.93297.24188.6857.9182.47126.55107.67
Short-Term Debt59.03K0000012.59M10.59M6.97M
Deferred Revenue (Current)701.84K192.53K360.71K415.77K0654.75K873.25K2.22M864.91K
Other Current Liabilities643.5K000132.34K02.37M2.21M2.77M
Current Ratio0.62x1.12x0.62x1.36x4.60x13.15x0.16x0.10x0.20x
Quick Ratio0.62x1.12x0.62x1.36x4.60x13.15x0.16x0.10x0.20x
Cash Conversion Cycle-1.25K------1.12-15.17
Total Non-Current Liabilities195.96K211.87K268.8K29.13K27.4K3.42M11.35M11.17M11.17M
Long-Term Debt195.96K00003.42M178.9K00
Capital Lease Obligations452.78K211.87K268.8K29.13K27.4K0000
Deferred Tax Liabilities000000000
Other Non-Current Liabilities00000011.17M00
Total Liabilities5.8M6.44M6.04M6.08M4.31M5.93M33.49M26.93M22.47M
Total Debt254.99K268.8K312.17K196.24K185.85K3.42M12.77M10.59M6.97M
Net Debt-2.56M-6.61M-1.57M-2.15M-15.12M-24.32M12.07M10.54M5.84M
Debt / Equity0.31x0.09x0.09x0.02x0.01x0.11x---
Debt / EBITDA-0.03x--------
Net Debt / EBITDA0.30x--------
Interest Coverage--5375.89x-57.58x-47.09x-41.88x-3.26x-1.22x-1.83x-3.51x
Total Equity814.04K3.09M3.31M9.74M20.31M29.79M-27.28M-22.72M-18.42M
Equity Growth %-182.55%-6.73%-66.01%-52.04%-31.83%209.21%-20.07%-23.31%-
Book Value per Share238.5126.84186.32861.891837.102916.17-23314.50-19417.73-15733.35
Total Shareholders' Equity814.04K3.09M3.31M9.74M20.31M29.79M-27.28M-22.72M-18.42M
Common Stock2.97K84817090889287394537537
Retained Earnings-84.63M-82.35M-71.86M-59.36M-48.27M-38.02M-29.06M-24.41M-19.75M
Treasury Stock-172-172-172-172-172-172-172-172-172
Accumulated OCI0008400000-159.83K
Minority Interest000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and solvency distress

Liquidity Buffer Rapidly Eroding

According to recent SEC filings, iSpecimen's current ratio has deteriorated significantly, falling from 1.36 in 2023Q4 to a precarious 0.62 in 2026Q1, which indicates that the company's ability to cover short-term obligations with existing liquid assets is increasingly compromised by persistent operational cash burn.

The decline in the current ratio suggests that the company is struggling to maintain sufficient working capital to support its ongoing operations. Investors should monitor the cash runway closely, as the current liquidity profile appears insufficient to sustain the business without further external financing or a drastic reduction in overhead.

Equity Erosion Through Accumulated Losses

As reported in financial statements, iSpecimen's equity base has contracted from $9.7M in 2023Q4 to $814.0K in 2026Q1, a trend primarily driven by the relentless accumulation of losses, which reached -$84.6M in retained earnings as of the most recent quarter.

The rapid depletion of shareholder equity highlights the company's inability to achieve profitability, effectively consuming the capital base provided by investors. This trajectory suggests that the company may be approaching a point where equity could turn negative, potentially triggering concerns regarding long-term solvency.

Goodwill Impairment Risks Loom Large

Based on iSpecimen's reported figures, the company's asset composition is heavily skewed by intangible assets, with goodwill fluctuating significantly and currently standing at $2.8M, which represents a substantial portion of the $6.6M total asset base as of 2026Q1.

The presence of significant goodwill on a balance sheet characterized by declining revenue and negative margins warrants further investigation into potential impairment risks. If the underlying business units fail to generate expected returns, these intangible assets may require write-downs, further pressuring the already fragile equity position.

Balance Sheet Weakening Over Time

Data from historical filings indicates that iSpecimen's balance sheet has weakened consistently over the last ten quarters, with total assets declining from $15.8M in 2023Q4 to $6.6M in 2026Q1, reflecting a broader trend of asset liquidation and capital depletion.

The consistent contraction across key balance sheet metrics suggests that the company is struggling to maintain its operational scale. This downward trajectory appears to be a direct consequence of the company's inability to align its cost structure with its transactional revenue model, signaling a high degree of business risk.

ISPC — Frequently Asked Questions

Quick answers to the most common questions about buying ISPC stock.

What are the total assets of iSpecimen Inc. (ISPC)?

As of 2025, iSpecimen Inc. (ISPC) had total assets of $9.5M including $7.0M in current assets.

How much debt does iSpecimen Inc. (ISPC) have?

iSpecimen Inc. (ISPC) carries total debt of $0.3M, offset by $6.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of iSpecimen Inc.?

iSpecimen Inc. (ISPC) has total shareholders' equity (book value) of $3.1M ($26.84 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is iSpecimen Inc.'s current ratio and liquidity?

iSpecimen Inc. (ISPC) reported a current ratio of 1.12x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.